Intervention not reported
Elective termination/induced abortion · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in elective termination/induced abortion (high certainty).
1 finding from 1 review
Intervention not reported
Stillbirth · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in stillbirth (moderate certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
Babies born with congenital malformations · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in babies born with congenital malformations (moderate certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention showed no clear difference in any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN3+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any AIS irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower any AIS irrespective of HPV type (moderate certainty).
1 finding from 1 review
All‐cause mortality · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in mortality compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Postoperative transfusion Median · People with cancer with perioperative thromboprophylaxis
1 finding from 1 review
Intraoperative blood loss (mL) · People with cancer with perioperative thromboprophylaxis
1 finding from 1 review
Postoperative drain volume · People with cancer with perioperative thromboprophylaxis
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Mortality ‐ not reported · People with cancer with perioperative thromboprophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total VTE · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in any VTE compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in major Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review